Patent Expirations and the Changing Landscape of Iodinated Contrast Media Market

The iodinated contrast media market in interventional X-Ray is poised for substantial growth from 2023 to 2030, driven by the high prevalence of cardiovascular disease and the expiration of patents, leading to increased competition and price reduction. This will enhance accessibility to the advantages of this technology for a larger population.

Access Full Report at https://www.databridgemarketresearch.com/de/reports/global-iodinated-contrast-media-in-interventional-x-ray-market

Data Bridge Market Research analyses that the Iodinated Contrast Media in Interventional X-Ray Market CAGR tends to be around 5.80% in the mentioned forecast period of 2023-2030. The market was valued at USD 2,497.3 million in 2022, and it would grow up to USD 3,920.63 million by 2030.  The aging population is more prone to chronic diseases that require interventional procedures. As the geriatric population increases, the demand for interventional X-ray and iodinated contrast media is expected to grow, driving market expansion.

Key Findings of the Study

The growing elderly population is expected to drive the market's growth rate

The elderly population is more susceptible to various cardiovascular conditions, including coronary artery disease, stroke, and peripheral vascular disease. With the aging population, there is an increased demand for interventional X-ray procedures, thereby fueling the use of iodinated contrast media.

Report Scope and Market Segmentation

Segment Analysis:

The iodinated contrast media in interventional X-Ray market is segmented on the basis of route of administration, indication, agent type, and end-user and distribution channel.

• On the basis of route of administration, the iodinated contrast media in interventional X-Ray market is segmented into intravenous, oral, rectal, others. The intravenous segment is expected to dominate the route of administration in the global iodinated contrast media in interventional x-ray market with 81.39% market share due to widespread use and effectiveness in various medical imaging procedures

In 2023 Intravenous segment is dominating the route of administration segment in iodinated contrast media in interventional X-Ray market

In 2023 Intravenous segment is dominating the route of administration segment in iodinated contrast media in interventional X-Ray market with the market share of 81.39% due to its widespread use and effectiveness in various medical imaging procedures. IV administration allows for direct delivery of the contrast agent into the bloodstream, ensuring rapid and uniform distribution throughout the body. This route of administration enables better visualization of blood vessels and organs, making it a preferred choice for interventional X-ray and other imaging techniques.

• On the basis of indication, the iodinated contrast media in interventional X-Ray market is segmented into cardiology, neurology, general surgery, oncology, and urology. Cardiology segment is dominating the indication segment in the iodinated contrast media in interventional x-ray market with the CAGR of 6.0% due to Iodinated contrast media are extensively used in cardiac catheterization, angiography, and other cardiac interventions.

 These procedures require accurate visualization of blood vessels and cardiac structures, and iodinated contrast media provide excellent opacification and contrast enhancement, making them essential in cardiology for diagnosis, treatment planning, and guiding interventional procedures. In the forecast period of 2023 to 2030.

• On the basis of agent type, the iodinated contrast media in interventional X-Ray market is segmented into non-ionic, ionic. Non-ionic segment dominates the agent type segment in the iodinated contrast media in interventional X-Ray market with the CAGR of 5.7% due to their improved safety profile and reduced risk of adverse reactions. Non-ionic agents have lower osmolality, making them better tolerated by patients, especially those with underlying renal conditions.
• On the basis of end user, the iodinated contrast media in interventional X-Ray market is segmented into hospital/clinical laboratories, physician offices, reference laboratories and other end users. Hospital segment dominates the end user segment of iodinated contrast media in interventional X-Ray market with the CAGR of 4.6% due to their role as major healthcare providers and centers for interventional procedures. Hospitals have dedicated radiology departments equipped with advanced imaging technologies, making them the primary location for interventional X-ray procedures.
• On the basis of distribution channel, iodinated contrast media in interventional X-Ray market is segmented into direct tender, retail sales, and other,

Major Players

Data Bridge Market Research recognizes the following companies as the major Iodinated contrast media in interventional X-Ray market players in iodinated contrast media in interventional X-Ray market are Bayer AG (Germany), Iso-Tex Diagnostics, Inc. (U.S.), Bracco Diagnostic Inc. (Italy), Novalek Pharmaceuticals Pvt. Ltd. (India),

Market Development

• In 2021, GE Healthcare expanded its ultrasound capabilities by acquiring BK Medical, allowing them to enter the field of surgical imaging and enhance precision health development.
• In, 2021 Koninklijke Philips N.V. partnered with DiA Imaging Analysis Ltd. to improve operational efficiency and access to care for point-of-care (POC) clients, both within and outside of hospitals, by integrating DiA's automated solutions with Philips ultrasound devices.
• In 2019, General Electric collaborated with Daiichi Sankyo Company to transfer marketing rights for four diagnostic imaging agents in Japan to GE Healthcare, strengthening their presence in the Japanese market.

Regional Analysis

Geographically, the countries covered in the iodinated contrast media in interventional X-ray market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in iodinated contrast media in interventional X-Ray market during the forecast period of 2023 to 2030

North America's dominance in the market is attributed to the widespread use of iodinated contrast materials in CT procedures, coupled with the availability of non-ionic stable iodinated agents for enhanced diagnosis. Government initiatives to raise awareness about cancer and cardiac diagnosis, along with the launch of innovative contrast agent products, contribute to the projected growth rate in the region. 

Asia-Pacific is estimated to be the fastest growing region in iodinated contrast media in interventional x-ray market the forecast period 2023 - 2030

Asia-Pacific holds the highest market share due to the high adoption of imaging techniques and the increased availability of non-ionic stable iodinated agents for improved diagnosis. The growing healthcare expenditure and the rise in the number of hospitals and imaging centers in countries like China and India drive the demand for iodinated contrast media in interventional X-ray procedures, fueling market growth in the region.

For more detailed information about the Iodinated Contrast Media in Interventional X-Ray Market report, click here – https://www.databridgemarketresearch.com/de/reports/global-iodinated-contrast-media-in-interventional-x-ray-market